Carcinogenesis, Vol. 21, No. 4, 793-797,
April 2000
© 2000 Oxford University Press
Carcinogenesis |
Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia
MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester LE1 9HN, UK
Tamoxifen was administered orally to neonatal rats on days 2–5 after birth and the subsequent effects on the uterus were characterized, morphometrically, over the following 12 months. Tamoxifen inhibited development of the uterus and glands in the endometrium, indicating a classical oestrogen antagonist action. Between 24 and 35 months after tamoxifen treatment there was a significant increase in the incidence (26%) of uterine adenocarcinomas and a 9% incidence of squamous cell carcinomas of the vagina/cervix in the absence of any oestrogen agonist effect in the uterus. This demonstrates that an oestrogen agonist effect is not an absolute requirement for the carcinogenic effect of tamoxifen in the reproductive tract of the rat. The unopposed oestrogen agonist effect of tamoxifen on the endometrium may not be the only factor involved in the development of endometrial cancers. It is possible that tamoxifen causes these tumours via a genotoxic mechanism similar to that seen in rat liver. However, using 32P-post-labelling we failed to find evidence of tamoxifen-induced DNA adducts in the uterus. Tamoxifen may affect hormonal imprinting of oestrogen receptor responses in stem cells of the uterus, causing reproductive tract cancers to arise at a later time, in the same way as has been proposed for diethylstilbestrol. If these rodent data extrapolate to humans, then women who are taking tamoxifen as a chemopreventative may have an increased risk of vaginal/cervical cancer, as well as endometrial cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Osipo, K. Meeke, H. Liu, D. Cheng, S. Lim, A. Weichel, and V. C. Jordan Trastuzumab Therapy for Tamoxifen-Stimulated Endometrial Cancer Cancer Res., September 15, 2005; 65(18): 8504 - 8513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Lelliott, M. Lopez, R. K. Curtis, N. Parker, M. Laudes, G. Yeo, M. Jimenez-Linan, J. Grosse, A. K. Saha, D. Wiggins, et al. Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis FASEB J, July 1, 2005; 19(9): 1108 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Phillips, A. Hewer, M. R. Osborne, K. J. Cole, C. Churchill, and V. M. Arlt Organ specificity of DNA adduct formation by tamoxifen and {alpha}-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment Mutagenesis, July 1, 2005; 20(4): 297 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Schild, R. L. Divi, F. A. Beland, M. I. Churchwell, D. R. Doerge, G. Gamboa da Costa, M. M. Marques, and M. C. Poirier Formation of Tamoxifen-DNA Adducts in Multiple Organs of Adult Female Cynomolgus Monkeys Dosed with Tamoxifen for 30 Days Cancer Res., September 15, 2003; 63(18): 5999 - 6003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Poirier and L. J. Schild The Genotoxicity of Tamoxifen: Extent and Consequences, Kona, Hawaii, January 23, 2003 Mutagenesis, July 1, 2003; 18(4): 395 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yadollahi-Farsani, D. S. Davies, and A. R. Boobis The mutational signature of {alpha}-hydroxytamoxifen at Hprt locus in Chinese hamster cells Carcinogenesis, November 1, 2002; 23(11): 1947 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yoshida, S.-i. Katsuda, T. Tanimoto, S. Asai, D. Nakae, Y. Kurokawa, K. Taya, and A. Maekawa Induction of different types of uterine adenocarcinomas in Donryu rats due to neonatal exposure to high-dose p-t-octylphenol for different periods Carcinogenesis, October 1, 2002; 23(10): 1745 - 1750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Miller, M. A. Marty, A. Arcus, J. Brown, D. Morry, and M. Sandy Differences Between Children and Adults: Implications for Risk Assessment at California EPA International Journal of Toxicology, September 1, 2002; 21(5): 403 - 418. [Abstract] [PDF]
|
|
|
|
|
|
M. Takahashi, T. Shimomoto, K. Miyajima, S. Iizuka, T. Watanabe, M. Yoshida, Y. Kurokawa, and A. Maekawa Promotion, but not progression, effects of tamoxifen on uterine carcinogenesis in mice initiated with N-ethyl-N'-nitro-N-nitrosoguanidine Carcinogenesis, September 1, 2002; 23(9): 1549 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gamboa da Costa, L.P. McDaniel-Hamilton, R. H. Heflich, M.M. Marques, and F. A. Beland DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives Carcinogenesis, August 1, 2001; 22(8): 1307 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Phillips Understanding the genotoxicity of tamoxifen? Carcinogenesis, June 1, 2001; 22(6): 839 - 849. [Abstract] [Full Text] [PDF]
|
|